Phase II Multicenter, Open-Label Study of Oral ENMD-2076 for the Treatment of Patients with Advanced Fibrolamellar Carcinoma.
Saved in:
| Title: | Phase II Multicenter, Open-Label Study of Oral ENMD-2076 for the Treatment of Patients with Advanced Fibrolamellar Carcinoma. |
|---|---|
| Authors: | Abou-Alfa GK; Weill Medical College at Cornell University, New York, New York, USA.; Memorial Sloan Kettering Cancer Center, New York, New York, USA., Mayer R; Dana-Farber Cancer Institute, Harvard University, Boston, Massachusetts, USA., Venook AP; University of California San Francisco, San Francisco, California, USA., O'Neill AF; Dana-Farber Cancer Institute, Harvard University, Boston, Massachusetts, USA., Beg MS; UT Southwestern Medical Center, Dallas, Texas, USA., LaQuaglia M; Weill Medical College at Cornell University, New York, New York, USA.; Memorial Sloan Kettering Cancer Center, New York, New York, USA., Kingham PT; Weill Medical College at Cornell University, New York, New York, USA.; Memorial Sloan Kettering Cancer Center, New York, New York, USA., Kobos R; Weill Medical College at Cornell University, New York, New York, USA.; Memorial Sloan Kettering Cancer Center, New York, New York, USA., Basturk O; Weill Medical College at Cornell University, New York, New York, USA.; Memorial Sloan Kettering Cancer Center, New York, New York, USA., Brennan C; Weill Medical College at Cornell University, New York, New York, USA.; Memorial Sloan Kettering Cancer Center, New York, New York, USA., Yopp A; UT Southwestern Medical Center, Dallas, Texas, USA., Harding JJ; Weill Medical College at Cornell University, New York, New York, USA.; Memorial Sloan Kettering Cancer Center, New York, New York, USA., Leong S; University of Colorado Cancer Center, Aurora, Colorado, USA., Crown J; St Vincent's Private Hospital, Dublin, Ireland., Hoti E; St Vincent's Private Hospital, Dublin, Ireland., Leonard G; Galway University Hospital, Galway, Ireland., Ly M; Memorial Sloan Kettering Cancer Center, New York, New York, USA., Bradley M; Memorial Sloan Kettering Cancer Center, New York, New York, USA., Valentino E; Memorial Sloan Kettering Cancer Center, New York, New York, USA., Markowitz D; CASI Pharmaceuticals, Inc., Rockville, Maryland, USA., Zukiwski A; CASI Pharmaceuticals, Inc., Rockville, Maryland, USA., Ren K; CASI Pharmaceuticals, Inc., Rockville, Maryland, USA., Gordan JD; University of California San Francisco, San Francisco, California, USA. |
| Source: | The oncologist [Oncologist] 2020 Dec; Vol. 25 (12), pp. e1837-e1845. Date of Electronic Publication: 2020 Mar 10. |
| Publication Type: | Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Oxford University Press Country of Publication: England NLM ID: 9607837 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1549-490X (Electronic) Linking ISSN: 10837159 NLM ISO Abbreviation: Oncologist Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
